NCT00537498View on ClinicalTrials.gov

Urokinase Therapy in Diabetic Foot Syndrome

PHASE2CompletedINTERVENTIONAL
Enrollment

77

Participants

Timeline

Start Date

February 28, 2002

Study Completion Date

December 31, 2006

Conditions
Diabetic FootArterial Occlusive DiseaseIschemia
Interventions
DRUG

Urokinase

"Daily intravenous application of urokinase over 30 minutes~Dosage:~If plasma fibrinogen is \> 2,5g/l application of 1 000 000 IU Urokinase If plasma fibrinogen is \< 2,5g/l application of 500 000 IU Urokinase If plasma fibrinogen is \< 1,6g/l treatment must be stopped and continued after rising up to \>2g/l"

Trial Locations (1)

01307

Universitätsklinikum Carl Gustav Carus UniversitätsGefäßcentrum, Dresden

All Listed Sponsors
lead

medac GmbH

INDUSTRY

NCT00537498 - Urokinase Therapy in Diabetic Foot Syndrome | Biotech Hunter | Biotech Hunter